Chicago, Illinois, United States In 2013 was created AbbVie, which is appeared as Corporate Investor. The main department of described Corporate Investor is located in the Chicago. The fund was located in North America if to be more exact in United States.
Among the most popular fund investment industries, there are Biotechnology, Health Diagnostics. Among the most popular portfolio startups of the fund, we may highlight Lodo Therapeutics. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States.
The standard case for the fund is to invest in rounds with 4-5 partakers. Despite the AbbVie, startups are often financed by Takeda Pharmaceutical, National Institutes of Health. The meaningful sponsors for the fund in investment in the same round are Pfizer Venture Investments, Johnson & Johnson Innovation, Eli Lilly. In the next rounds fund is usually obtained by National Institutes of Health, Alzheimer's Association.
Deals in the range of 10 - 50 millions dollars are the general things for fund. The fund is constantly included in less than 2 investment rounds annually. Considering the real fund results, this Corporate Investor is 30 percentage points more often commits exit comparing to other organizations. The top activity for fund was in 2016.
Related Funds
| Fund Name | Location |
| Advent Life Sciences | England, London, United Kingdom |
| Changzhou Hongtu Venture Capital | - |
| China Investment & Development | - |
| CloudWise | Beijing, Beijing, China |
| Huatai Insurance Group | Beijing, Beijing, China |
| Impacton | - |
| Lincoln Financial Group | Pennsylvania, Radnor, United States |
| McDATA Corporation | Broomfield, Colorado, United States |
| Miele Venture | - |
| Newlight Partners | New York, New York, United States |
| Old Willow Partners | Minnesota, Northfield, United States |
| Prisma Capital | Brazil, Itaim, Minas Gerais |
| Renhuai Jiu Tou | China, Guizhou, Zunyi |
| Sofipaca | Aix-en-Provence, France, Provence-Alpes-Côte d'Azur |
| Sova VC | England, London, United Kingdom |
| SRB Management | Dallas, Texas, United States |
| Sud Partners | France, Lyon, Rhone-Alpes |
| The Al Muhaidib Group | - |
| Urca Angels | Brazil, São Paulo, Sao Paulo |
| Zhonghang Dexing | China, Fujian, Xiamen Shi |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Kojin Therapeutics | $60M | 09 Jun 2021 | Cambridge, Massachusetts, United States | ||
Lodo Therapeutics | $17M | 11 Jan 2016 | New York, New York, United States | ||
Petra Pharma | $48M | 06 Jan 2016 | New York, United States |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Kojin Therapeutics | $60M | 09 Jun 2021 | Cambridge, Massachusetts, United States | ||
Lodo Therapeutics | $17M | 11 Jan 2016 | New York, New York, United States | ||
Petra Pharma | $48M | 06 Jan 2016 | New York, United States |
